Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (5,887,157)	$ (12,065,538)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Subsidiary Stock issued for compensation	3,000
Subsidiary Stock issued for services rendered by consultants	40
Interest Expense attributable to amortization of discount	154,407	77,419
Additional paid in Capital	743,216	681,274
Impairment of Available for sale Securities
Loss on Settlement of Debt through Equity Issuance	3,276,933	10,093,387
Changes in operating assets and liabilities:
(Increase) Decrease in Prepaid Expenses	9,000	(6,289)
Increase (Decrease) in Accounts Payable	121,766	(14,830)
Increase (Decrease) in Accrued Expenses	276,575	140,804
Increase (Decrease) in bank Overdraft		(6,137)
(Increase) Decrease in Interest Receivable	(897)	(848)
(Increase) Decrease in Due from Former Employee	(15,000)
Decrease (Increase) Note Receivable		(1,629)
Net Cash Provided by (Used in) Operating Activities	(1,318,117)	(1,102,387)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in due to subsidiary shareholder	0	0
Stock in subsidiary sold for cash	1,154,751
Principal borrowings (repayments) on notes and Convertible Debentures	79,097	60,103
Principal borrowings (repayments) on Convertible Debentures	150,000	1,272,686
(Increase) Decrease in Deferred Financing Costs
Net Cash Provided by (Used in) Financing Activities	1,383,848	1,332,789
Net Increase (Decrease) in Cash	65,731	230,402
Cash at Beginning of Period	76,355	502
Cash at End of Period	142,086	230,904
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	178,951	157,500
Common Shares of Regen Biopharma, Inc. issued for debt	14,000	972,686
Preferred Shares of Regen Biopharma, inc. issued for debt	$ 10,000